Pojer Florence, Ferrer Jean-Luc, Richard Stéphane B, Nagegowda Dinesh A, Chye Mee-Len, Bach Thomas J, Noel Joseph P
Howard Hughes Medical Institute, The Jack H. Skirball Center for Chemical Biology and Proteomics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11491-6. doi: 10.1073/pnas.0604935103. Epub 2006 Jul 24.
3-Hydroxy-3-methylglutaryl CoA synthase (HMGS) catalyzes the first committed step in the mevalonate metabolic pathway for isoprenoid biosynthesis and serves as an alternative target for cholesterol-lowering and antibiotic drugs. We have determined a previously undescribed crystal structure of a eukaryotic HMGS bound covalently to a potent and specific inhibitor F-244 [(E,E)-11-[3-(hydroxymethyl)-4-oxo-2-oxytanyl]-3,5,7-trimethyl-2,4-undecadienenoic acid]. Given the accessibility of synthetic analogs of the F-244 natural product, this inhibited eukaryotic HMGS structure serves as a necessary starting point for structure-based methods that may improve the potency and species-specific selectivity of the next generation of F-244 analogs designed to target particular eukaryotic and prokaryotic HMGS.
3-羟基-3-甲基戊二酰辅酶A合酶(HMGS)催化甲羟戊酸代谢途径中异戊二烯生物合成的首个关键步骤,是降胆固醇药物和抗生素的另一个作用靶点。我们确定了一种真核生物HMGS与一种强效特异性抑制剂F-244 [(E,E)-11-[3-(羟甲基)-4-氧代-2-氧代戊基]-3,5,7-三甲基-2,4-十一碳二烯酸]共价结合的晶体结构,该结构此前未曾报道。鉴于F-244天然产物合成类似物的可得性,这种被抑制的真核生物HMGS结构是基于结构方法的必要起点,这些方法可能会提高下一代旨在靶向特定真核生物和原核生物HMGS的F-244类似物的效力和物种特异性选择性。